- Home
- SXTP vs QLGN Comparison
SXTP vs QLGN Comparison
Compare SXTP & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SXTP
- QLGN
- Stock Information
- Founded
- SXTP 2010
- QLGN 1996
- Country
- SXTP United States
- QLGN United States
- Employees
- SXTP N/A
- QLGN N/A
- Industry
- SXTP Biotechnology: Pharmaceutical Preparations
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- SXTP Health Care
- QLGN Health Care
- Exchange
- SXTP Nasdaq
- QLGN Nasdaq
- Market Cap
- SXTP 2.7M
- QLGN 2.2M
- IPO Year
- SXTP 2023
- QLGN N/A
- Fundamental
- Price
- SXTP $2.26
- QLGN $3.59
- Analyst Decision
- SXTP Hold
- QLGN
- Analyst Count
- SXTP 1
- QLGN 0
- Target Price
- SXTP N/A
- QLGN N/A
- AVG Volume (30 Days)
- SXTP 457.4K
- QLGN 48.9K
- Earning Date
- SXTP 05-19-2025
- QLGN 07-01-2025
- Dividend Yield
- SXTP N/A
- QLGN N/A
- EPS Growth
- SXTP N/A
- QLGN N/A
- EPS
- SXTP N/A
- QLGN N/A
- Revenue
- SXTP $681,345.00
- QLGN N/A
- Revenue This Year
- SXTP $95.50
- QLGN N/A
- Revenue Next Year
- SXTP $80.78
- QLGN N/A
- P/E Ratio
- SXTP N/A
- QLGN N/A
- Revenue Growth
- SXTP 168.70
- QLGN N/A
- 52 Week Low
- SXTP $1.41
- QLGN $2.85
- 52 Week High
- SXTP $36.00
- QLGN $29.45
- Technical
- Relative Strength Index (RSI)
- SXTP 43.50
- QLGN 54.52
- Support Level
- SXTP $2.21
- QLGN $3.40
- Resistance Level
- SXTP $2.45
- QLGN $3.73
- Average True Range (ATR)
- SXTP 0.44
- QLGN 0.37
- MACD
- SXTP -0.09
- QLGN 0.00
- Stochastic Oscillator
- SXTP 6.86
- QLGN 36.79
About SXTP 60 Degrees Pharmaceuticals Inc.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.